Results 61 to 70 of about 34,512 (245)

Blood plasma lipid profile in glial tumors

Успехи молекулярной онкологии
Introduction. In glial tumors, lipid metabolism becomes abnormal. Analysis of lipid metabolism components can be an important characteristic of molecular and genetic profile of gliomas.Aim. To determine the correlation between plasma lipidome profile and
L. M. Obukhova, E. V. Balavina, T. A. Veselova, I. A. Medyanik, A. S. Grishin, V. F. Lazukin, M. M. Kontorshchikov   +6 more
doaj   +1 more source

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer

Acta Pharmaceutica Sinica B, 2023
Reprogramming of energy metabolism is one of the basic characteristics of cancer and has been proved to be an important cancer treatment strategy. Isocitrate dehydrogenases (IDHs) are a class of key proteins in energy metabolism, including IDH1, IDH2 ...
Yang Liu, Wei Xu, Mingxue Li, Yueying Yang, Dejuan Sun, Lidian Chen, Hua Li, Lixia Chen   +7 more
doaj   +1 more source

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, EarlyView.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells

Cell Reports, 2018
Summary: Neomorphic mutations in NADP-dependent isocitrate dehydrogenases (IDH1 and IDH2) contribute to tumorigenesis in several cancers. Although significant research has focused on the hypermethylation phenotypes associated with (D)2-hydroxyglutarate ...
Mehmet G. Badur, Thangaselvam Muthusamy, Seth J. Parker, Shenghong Ma, Samuel K. McBrayer, Thekla Cordes, Jose H. Magana, Kun-Liang Guan, Christian M. Metallo   +8 more
doaj   +1 more source

Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. [PDF]

PLoS ONE, 2015
Glioblastoma can occur either de novo or by the transformation of a low grade tumour; the majority of which harbor a mutation in isocitrate dehydrogenase (IDH1). Anaplastic tumours are high-grade gliomas that may represent the final step in the evolution
Jason K Wasserman, Garth Nicholas, Rebecca Yaworski, Anne-Marie Wasserman, John M Woulfe, Gerard H Jansen, Santanu Chakraborty, Thanh B Nguyen   +7 more
doaj   +1 more source

The Roles of IDH1 in Tumor Metabolism and Immunity

Future Oncology, 2022
IDH1 is a key metabolic enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle that can convert isocitrate into α-ketoglutarate (α-KG) and generate NADPH. The reduction of IDH1 may affect dioxygenase activity and damage the body's detoxification mechanism.
Yingqian Ni, Peibo Shen, Xingchen Wang, He Liu, Huiyuan Luo, Xiuzhen Han   +5 more
openaire   +2 more sources

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

Arthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α [PDF]

Science, 2009
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 ( IDH1 ) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown. We have shown that tumor-derived IDH1 mutations impair the enzyme's affinity for its substrate and dominantly ...
Yan Lin, Shimin Zhao, Jianping Ding, Pu Wang, Wenqing Jiang, Zhiqiang Li, Wei Xu, Yue Xiong, Yue Xiong, Qun-Ying Lei, Lingling Gong, Kun-Liang Guan, Kun-Liang Guan, Wei Yu, Yingjie Peng, Zhengyu Zha   +15 more
openaire   +3 more sources

Breaking barriers: the cGAS‐STING pathway as a novel frontier in cancer immunotherapy

Cancer Communications, EarlyView.
Abstract Since its discovery, the cyclic GMP‐AMP synthase (cGAS)‐stimulator of the interferon gene (STING) signaling pathway has been considered a pivotal component of innate immunity and a promising target for cancer immunotherapy. Beyond its canonical role in pathogen defense, accumulating evidence has demonstrated that the cGAS‐STING pathway ...
Yuheng Yan, Ximin Tan, Bin Song, Ming Yi, Qian Chu, Kongming Wu   +5 more
wiley   +1 more source